4594.T Stock - BrightPath Biotherapeutics Co., Ltd.
Unlock GoAI Insights for 4594.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.13M | $72,000 | $5.28M | $15.41M | $2.50M |
| Gross Profit | $1.10M | $-341,000 | $3.38M | $12.09M | $1.36M |
| Gross Margin | 97.2% | -473.6% | 64.1% | 78.5% | 54.3% |
| Operating Income | $-1,160,918,000 | $-1,155,079,000 | $-1,467,059,000 | $-1,476,033,000 | $-1,732,802,000 |
| Net Income | $-1,151,149,000 | $-1,168,082,000 | $-1,485,633,000 | $-1,484,192,000 | $-1,719,634,000 |
| Net Margin | -101601.9% | -1622336.1% | -28137.0% | -9632.6% | -68675.5% |
| EPS | $-14.12 | $-18.21 | $-24.90 | $-28.55 | $-36.14 |
BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
4594.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-1.98 | — | — |
Q3 2025 | Aug 8, 2025 | — | $-2.59 | — | — |
Q2 2025 | May 9, 2025 | — | $-3.83 | — | — |
Q1 2025 | Feb 14, 2025 | — | $-3.19 | — | — |
Q4 2024 | Nov 8, 2024 | — | $-2.49 | — | — |
Q3 2024 | Aug 9, 2024 | — | $-4.66 | — | — |
Q2 2024 | May 10, 2024 | — | $-3.17 | — | — |
Q1 2024 | Feb 9, 2024 | — | $-6.32 | — | — |
Q4 2023 | Nov 10, 2023 | — | $-4.10 | — | — |
Q3 2023 | Aug 10, 2023 | — | $-4.70 | — | — |
Q2 2023 | May 12, 2023 | — | $-4.14 | — | — |
Q1 2023 | Feb 10, 2023 | — | $-6.73 | — | — |
Q4 2022 | Nov 11, 2022 | — | $-4.45 | — | — |
Q3 2022 | Aug 12, 2022 | — | $-9.75 | — | — |
Q2 2022 | May 11, 2022 | — | $-7.34 | — | — |
Q1 2022 | Feb 10, 2022 | — | $-6.77 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-6.13 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-8.68 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-7.93 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-9.91 | — | — |
Latest News
Frequently Asked Questions about 4594.T
What is 4594.T's current stock price?
What is the analyst price target for 4594.T?
What sector is BrightPath Biotherapeutics Co., Ltd. in?
What is 4594.T's market cap?
Does 4594.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4594.T for comparison